NV5 Stock Overview
Develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AcuCort AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.05 |
| 52 Week High | SEK 0.071 |
| 52 Week Low | SEK 0.05 |
| Beta | 0.87 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -21.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| NV5 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -17.6% | -1.7% | 0.6% |
| 1Y | n/a | -19.9% | 3.3% |
Return vs Industry: Insufficient data to determine how NV5 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how NV5 performed against the German Market.
Price Volatility
| NV5 volatility | |
|---|---|
| NV5 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: NV5's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NV5's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 3 | Jonas Jonmark | www.acucort.com |
AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
AcuCort AB (publ) Fundamentals Summary
| NV5 fundamental statistics | |
|---|---|
| Market cap | €7.48m |
| Earnings (TTM) | -€1.23m |
| Revenue (TTM) | €601.50k |
12.4x
P/S Ratio-6.1x
P/E RatioIs NV5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NV5 income statement (TTM) | |
|---|---|
| Revenue | SEK 6.81m |
| Cost of Revenue | SEK 15.30m |
| Gross Profit | -SEK 8.49m |
| Other Expenses | SEK 5.39m |
| Earnings | -SEK 13.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | -124.71% |
| Net Profit Margin | -203.80% |
| Debt/Equity Ratio | 0% |
How did NV5 perform over the long term?
See historical performance and comparison